Trial reportBone marrow transplantation2012
Successful treatment of metastatic retinoblastoma with high-dose chemotherapy and autologous stem cell rescue in South America.
Trial report in Bone marrow transplantation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 50 citations in OpenAlex.
- Efficacy and safety analysis of autologous hematopoietic stem cell transplantation for extraocular retinoblastoma.Frontiers in pediatrics · 2026Article
- Update on Retinoblastoma Therapies.Medicina (Kaunas, Lithuania) · 2025Review
- Clinical Analysis of 16 Distant Metastatic Retinoblastoma Cases with Event-Free Survival.Cancer management and research · 2022Article
- Characterization, treatment and prognosis of retinoblastoma with central nervous system metastasis.BMC ophthalmology · 2018Article
- Chemotherapy in Retinoblastoma: Current Approaches.Turkish journal of ophthalmology · 2015Review
- Management of retinoblastoma in children: current status.Paediatric drugs · 2015Review
- High-dose chemotherapy for high-risk retinoblastoma: clinical course and outcome of 14 cases in the National Cancer Center, Japan.Bone marrow transplantation · 2015Article
- Staging and monitoring of childhood rhabdomyosarcoma with flow cytometry.Oncology letters · 2014Article
- Retinoblastoma: an overview.Indian journal of pediatrics · 2012Review
- Metastatic retinoblastoma at presentation: Clinical presentation, treatment, and outcomes.Oman journal of ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-dose chemotherapy (HDC) followed by autologous stem cell rescue (ASCR) is the only curative treatment for metastatic retinoblastoma, but its feasibility in developing countries is unknown. We report 11 consecutive children (six unilateral) treated in three South-American middle-income countries with HDC-ASCR. One patient had metastatic retinoblastoma at diagnosis and the remaining ones had a metastatic relapse. Metastatic sites included BM=6, bone=4, orbit=5 and central nervous system (CNS)=4. All patients received induction with conventional chemotherapy achieving CR at a median of 5.7 months from the diagnosis of metastasis. Conditioning regimens included carboplatin and etoposide with thiotepa in six or with CY in four or melphalan in one patient. All patients engrafted after G-CSF-mobilized peripheral blood ASCR and no toxic deaths occurred. Two children received post-ASCR CNS radiotherapy. Seven children have disease-free survival (median follow-up 39 months). CNS relapse, isolated (n=3) or with systemic relapse (n=1), occurring at a median of 7 months after ASCT was the most common event. In the same period, five children with metastatic retinoblastoma did not qualify for HDC-ASCR and died. We conclude that HDC-ASCR is a feasible and effective treatment for children with metastatic retinoblastoma in middle-income countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.